Processa Pharmaceuticals shares are trading higher after the company announced efficacy results from a preliminary evaluation of its Phase 1b dose-escalating trial with NGC-Cap in gastrointestinal cancer.
Portfolio Pulse from Benzinga Newsdesk
Processa Pharmaceuticals shares are trading higher following the announcement of positive efficacy results from a preliminary evaluation of its Phase 1b dose-escalating trial with NGC-Cap in gastrointestinal cancer.
June 11, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Processa Pharmaceuticals shares are trading higher after the company announced positive efficacy results from a preliminary evaluation of its Phase 1b dose-escalating trial with NGC-Cap in gastrointestinal cancer.
The positive preliminary results from the Phase 1b trial are likely to boost investor confidence in Processa Pharmaceuticals' pipeline, leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100